While historically, HER2 expression has been an unfavorable prognostic factor in breast cancer, significant improvements in PFS and OS have been observed with the use of anti-HER2-based therapies, and in cervical cancer, treatments targeting VEGF, a mediator of the HIF1 pathway, may have eliminated the negative role of HIF1 expression [24]. This evidence concerns the gene VEGFA and cervical carcinoma.